{"success":true,"data":{"pressRelease":{"id":"161188","rtpr_id":"nGNE4hvj2l-20261006","ticker":"SASY","exchange":"Euronext Paris","all_tickers":["SASY"],"title":"REG-Press Release : Availability of the aide-mémoire for Q3 2026 results","author":"Globe Newswire","published_at":"2026-10-06T05:30:00.049Z","article_body":"Availability of the aide-mémoire for Q3 2026 results\n\nParis, France – October 6, 2026. Sanofi announced today the availability of\nthe aide-mémoire for Q3 2026 results on the \"Investors\" page of sanofi.com:\n\nThird quarter 2026 results\n(https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/q3-2026-results)\n\nPrepared each quarter, this document is intended to support financial\nmodelling of the quarterly results. It covers non-comparable items, foreign\ncurrency impact, and share count. Sanofi's Q3 2026 results will be published\non October 30, 2026.\n\nAbout Sanofi \nSanofi is an R&D driven, AI-powered biopharma company committed to improving\npeople’s lives and delivering compelling growth. We apply our deep\nunderstanding of the immune system to invent medicines and vaccines that treat\nand protect millions of people around the world, with an innovative pipeline\nthat could benefit millions more. Our team is guided by one purpose: we chase\nthe miracles of science to improve people’s lives; this inspires us to drive\nprogress and deliver positive impact for our people and the communities we\nserve, by addressing the most urgent healthcare, environmental, and societal\nchallenges of our time.\n\nSanofi is listed on EURONEXT: SAN and NASDAQ: SNY.\n\nMedia Relations\nSandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com \nEvan Berland | +1 215 432 0234 | evan.berland@sanofi.com  \nTimothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com \nLéo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com  \nVictor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com \nLéa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com\nEkaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com \n\nInvestor Relations\nThomas Kudsk Larsen | +44 7545 513 693 | thomas.larsen@sanofi.com\nAlizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com\nKeita Browne | +1 781 249 1766 | keita.browne@sanofi.com\nNathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com\nNina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com\nThibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com\nYun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com\n\nForward-looking statements\n\nThis press release contains forward-looking statements within the meaning of\napplicable securities laws, including the Private Securities Litigation Reform\nAct of 1995, as amended.\n\nForward-looking statements are statements that are not historical facts. These\nstatements include projections and estimates and their underlying assumptions,\nstatements regarding plans, objectives, intentions, and expectations with\nrespect to future financial results, events, operations, services, product\ndevelopment and potential, and statements regarding future events and economic\nperformance. Words such as “expect,” “anticipate,” “believe,”\n“intend,” “estimate,” “plan,” “can,” “contemplate,”\n“could,” “is designed to,” “may,” “might,” “potential,”\n“objective,” \"attempt,\" “target,” “project,” \"strategy,\" \"strive,\"\n\"desire,\" “predict,” “forecast,” “ambition,” “guideline,”\n\"seek,\" “should,” “will,” \"goal,\" or the negative of these, and\nsimilar expressions are intended to identify forward-looking statements.\n\nAlthough Sanofi’s management believes that the expectations reflected in\nsuch forward-looking statements are reasonable, investors are cautioned that\nforward-looking information and statements are subject to various risks and\nuncertainties, many of which are difficult to predict and generally beyond the\ncontrol of Sanofi, that could cause actual results and developments to differ\nmaterially from those expressed in, or implied or projected by, the\nforward-looking information and statements. These risks and uncertainties\ninclude among other things, the uncertainties inherent in research and\ndevelopment, future clinical data and analysis, including post marketing,\ndecisions by regulatory authorities, such as the U.S Food and Drug\nAdministration or the European Medicines Agency, regarding whether and when to\napprove any drug, device or biological application that may be filed for any\nsuch product candidates as well as their decisions regarding labelling and\nother matters that could affect the availability or commercial potential of\nsuch product candidates; the fact that product candidates if approved may not\nbe commercially successful; unexpected regulatory actions or delays, or\ngovernment regulation generally; authorities’ decisions regarding whether\nand when to approve a product candidate; political pressure in the United\nStates to mandate lower drug prices including “most favored nation”\npricing for State Medicaid programs; the future approval and commercial\nsuccess of therapeutic alternatives; Sanofi’s ability to benefit from\nexternal growth opportunities, to complete related transactions and/or obtain\nregulatory clearances, including future clinical data and analysis of existing\nclinical data relating to the product, including post marketing, unexpected\nsafety, quality or manufacturing issues, competition in general; risks\nassociated with intellectual property and any related pending or future\nlitigation and the ultimate outcome of such litigation; trends in exchange\nrates and prevailing interest rates, volatile economic and market conditions,\ncost containment initiatives and subsequent changes thereto, and the impact\nthat global crises may have on us, our customers, suppliers, vendors, and\nother business partners, and the financial condition of any one of them, as\nwell as on our employees and on the global economy as a whole. The risks and\nuncertainties also include the uncertainties discussed or identified in the\npublic filings with the SEC and the French Markets Authority (AMF) made by\nSanofi, including those listed under “Risk Factors” and “Cautionary\nStatement Regarding Forward-Looking Statements” in Sanofi’s annual report\non Form 20-F for the year ended December 31, 2025 or contained in our periodic\nreports on Form 6-K. Other than as required by applicable law, Sanofi does not\nundertake any obligation to update or revise any forward-looking information\nor statements. In light of these risks, uncertainties and assumptions, you\nshould not place undue reliance on any forward-looking statements contained\nherein.\n\nAttachment\n*     Press release\n(https://ml-eu.globenewswire.com/Resource/Download/ccb37726-78f7-4d2e-9b17-3a1ad0ad18f2)","article_body_html":"","raw_payload":{"data":{"id":"nGNE4hvj2l-20261006","title":"REG-Press Release : Availability of the aide-mémoire for Q3 2026 results","author":"Globe Newswire","ticker":"SASY","created":"2026-10-06T05:30:00.049Z","tickers":["SASY"],"exchange":"Euronext Paris","article_body":"Availability of the aide-mémoire for Q3 2026 results\n\nParis, France – October 6, 2026. Sanofi announced today the availability of\nthe aide-mémoire for Q3 2026 results on the \"Investors\" page of sanofi.com:\n\nThird quarter 2026 results\n(https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/q3-2026-results)\n\nPrepared each quarter, this document is intended to support financial\nmodelling of the quarterly results. It covers non-comparable items, foreign\ncurrency impact, and share count. Sanofi's Q3 2026 results will be published\non October 30, 2026.\n\nAbout Sanofi \nSanofi is an R&D driven, AI-powered biopharma company committed to improving\npeople’s lives and delivering compelling growth. We apply our deep\nunderstanding of the immune system to invent medicines and vaccines that treat\nand protect millions of people around the world, with an innovative pipeline\nthat could benefit millions more. Our team is guided by one purpose: we chase\nthe miracles of science to improve people’s lives; this inspires us to drive\nprogress and deliver positive impact for our people and the communities we\nserve, by addressing the most urgent healthcare, environmental, and societal\nchallenges of our time.\n\nSanofi is listed on EURONEXT: SAN and NASDAQ: SNY.\n\nMedia Relations\nSandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com \nEvan Berland | +1 215 432 0234 | evan.berland@sanofi.com  \nTimothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com \nLéo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com  \nVictor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com \nLéa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com\nEkaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com \n\nInvestor Relations\nThomas Kudsk Larsen | +44 7545 513 693 | thomas.larsen@sanofi.com\nAlizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com\nKeita Browne | +1 781 249 1766 | keita.browne@sanofi.com\nNathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com\nNina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com\nThibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com\nYun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com\n\nForward-looking statements\n\nThis press release contains forward-looking statements within the meaning of\napplicable securities laws, including the Private Securities Litigation Reform\nAct of 1995, as amended.\n\nForward-looking statements are statements that are not historical facts. These\nstatements include projections and estimates and their underlying assumptions,\nstatements regarding plans, objectives, intentions, and expectations with\nrespect to future financial results, events, operations, services, product\ndevelopment and potential, and statements regarding future events and economic\nperformance. Words such as “expect,” “anticipate,” “believe,”\n“intend,” “estimate,” “plan,” “can,” “contemplate,”\n“could,” “is designed to,” “may,” “might,” “potential,”\n“objective,” \"attempt,\" “target,” “project,” \"strategy,\" \"strive,\"\n\"desire,\" “predict,” “forecast,” “ambition,” “guideline,”\n\"seek,\" “should,” “will,” \"goal,\" or the negative of these, and\nsimilar expressions are intended to identify forward-looking statements.\n\nAlthough Sanofi’s management believes that the expectations reflected in\nsuch forward-looking statements are reasonable, investors are cautioned that\nforward-looking information and statements are subject to various risks and\nuncertainties, many of which are difficult to predict and generally beyond the\ncontrol of Sanofi, that could cause actual results and developments to differ\nmaterially from those expressed in, or implied or projected by, the\nforward-looking information and statements. These risks and uncertainties\ninclude among other things, the uncertainties inherent in research and\ndevelopment, future clinical data and analysis, including post marketing,\ndecisions by regulatory authorities, such as the U.S Food and Drug\nAdministration or the European Medicines Agency, regarding whether and when to\napprove any drug, device or biological application that may be filed for any\nsuch product candidates as well as their decisions regarding labelling and\nother matters that could affect the availability or commercial potential of\nsuch product candidates; the fact that product candidates if approved may not\nbe commercially successful; unexpected regulatory actions or delays, or\ngovernment regulation generally; authorities’ decisions regarding whether\nand when to approve a product candidate; political pressure in the United\nStates to mandate lower drug prices including “most favored nation”\npricing for State Medicaid programs; the future approval and commercial\nsuccess of therapeutic alternatives; Sanofi’s ability to benefit from\nexternal growth opportunities, to complete related transactions and/or obtain\nregulatory clearances, including future clinical data and analysis of existing\nclinical data relating to the product, including post marketing, unexpected\nsafety, quality or manufacturing issues, competition in general; risks\nassociated with intellectual property and any related pending or future\nlitigation and the ultimate outcome of such litigation; trends in exchange\nrates and prevailing interest rates, volatile economic and market conditions,\ncost containment initiatives and subsequent changes thereto, and the impact\nthat global crises may have on us, our customers, suppliers, vendors, and\nother business partners, and the financial condition of any one of them, as\nwell as on our employees and on the global economy as a whole. The risks and\nuncertainties also include the uncertainties discussed or identified in the\npublic filings with the SEC and the French Markets Authority (AMF) made by\nSanofi, including those listed under “Risk Factors” and “Cautionary\nStatement Regarding Forward-Looking Statements” in Sanofi’s annual report\non Form 20-F for the year ended December 31, 2025 or contained in our periodic\nreports on Form 6-K. Other than as required by applicable law, Sanofi does not\nundertake any obligation to update or revise any forward-looking information\nor statements. In light of these risks, uncertainties and assumptions, you\nshould not place undue reliance on any forward-looking statements contained\nherein.\n\nAttachment\n*     Press release\n(https://ml-eu.globenewswire.com/Resource/Download/ccb37726-78f7-4d2e-9b17-3a1ad0ad18f2)"},"type":"article","timestamp":"2026-10-06T05:30:00.144114226Z","server_sent_at_ms":1791264600144},"received_at":"2026-10-06T05:30:00.195Z","source_url":null},"analysis":{"id":"149731","press_release_id":"161188","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Sanofi announced the availability of its Q3 2026 aide-mémoire, a document supporting financial modelling of quarterly results.\n\nThe document covers non-comparable items, foreign currency impact, and share count, and is posted on the Investors page of sanofi.com.\n\nQ3 2026 results will be published on October 30, 2026; this is a routine pre-earnings scheduling notice with no new financial data.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine notice — Q3 2026 earnings date confirmed for October 30, 2026; no action needed."},"keyFigures":{"customDimensions":{"earnings_date":"October 30, 2026"}},"namedEntities":{"people":[],"products":[],"companies":[{"name":"Sanofi","ticker":"SASY","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Boilerplate announcement that a quarterly results aide-mémoire document is available ahead of Q3 2026 earnings on October 30, 2026. No new financial or operational information."},"tickerRelevance":{"others":[{"ticker":"SNY","relevance":"US-listed line of the same issuer (NASDAQ)"}],"primary":"SASY"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mega-cap","eventGravity":"routine-scheduling-notice","householdBrandBoost":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Sanofi announced the availability of its Q3 2026 aide-mémoire, a document supporting financial modelling of quarterly results.\n\nThe document covers non-comparable items, foreign currency impact, and share count, and is posted on the Investors page of sanofi.com.\n\nQ3 2026 results will be published on October 30, 2026; this is a routine pre-earnings scheduling notice with no new financial data.","key_figures":{"customDimensions":{"earnings_date":"October 30, 2026"}},"named_entities":{"people":[],"products":[],"companies":[{"name":"Sanofi","ticker":"SASY","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T05:30:04.414Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"mega-cap","eventGravity":"routine-scheduling-notice","householdBrandBoost":false}},"durationMs":4207,"modelName":"glm-5.3-flashx"}}